Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1647 1657
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17639862 | TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS | Final Rejection | Novartis AG |
| 18026546 | POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17428995 | TREATMENT OF PATIENTS AT RISK OF RAPID PROGRESSION OF OSTEOARTHRITIS WITH AN FGF-18 COMPOUND | Non-Final OA | MERCK PATENT GMBH |
| 18327577 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA | Non-Final OA | Janssen Biotech, Inc. |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | Non-Final OA | Maddon Advisors LLC |
| 18523811 | Ligand Binding Molecules and Uses Thereof | Non-Final OA | VEGENICS PTY LIMITED |
| 17606173 | METHODS FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS WITH BEVACIZUMAB LINKED TO HEPARIN | Final Rejection | The University of Massachusetts |
| 18491616 | LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | YUHAN CORPORATION |
| 17999903 | RHFGF21 FUSION PROTEIN, POLYNUCLEOTIDE ENCODING RHFGF21 FUSION PROTEIN, COMPOSITION CONTAINING RHFGF21 FUSION PROTEIN, AND USE OF RHFGF21 FUSION PROTEIN | Non-Final OA | Jiangsu Kanion Pharmaceutical Co., Ltd. |
| 18256276 | HALF-LIFE EXTENDING COMPOSITIONS AND METHODS | Non-Final OA | Janux Therapeutics, Inc. |
| 18319817 | METHODS AND ANTIBODIES FOR MODULATION OF IMMUNORESPONSE | Non-Final OA | Ascendo Biotechnology, Inc. |
| 18030089 | METHOD OF TREATMENT OF FIBROSIS AND WOUND HEALING | Non-Final OA | RADBIO USA, Inc |
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | Non-Final OA | SPHINGOTEC GMBH |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | Final Rejection | SphingoTec GmbH |
| 16315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | Non-Final OA | Sphingotec GmbH |
| 18072750 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE CONTAINING BONE MORPHOGENETIC PROTEIN 10 AS ACTIVE INGREDIENT | Final Rejection | GIL MEDICAL CENTER |
| 16646495 | PROADRENOMEDULLIN AS INDICATOR FOR RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS | Final Rejection | B.R.A.H.M.S GmbH |
| 17905607 | ANTIGEN-BINDING MOLECULES AND USES THEREOF | Non-Final OA | Scout Bio, Inc. |
| 17905496 | PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB | Non-Final OA | SHANGHAI HENLIUS BIOTECH, INC. |
| 17837920 | Heparin-Associated Polypeptides and Uses Thereof | Non-Final OA | Juvena Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy